Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Miehsler, W; Dejaco, C; Gröchenig, HP; Fuchssteiner, H; Högenauer, C; Kazemi-Shirazi, L; Maier, H; Mayer, A; Moschen, A; Reinisch, W; Petritsch, W; Platzer, R; Steiner, P; Tilg, H; Vogelsang, H; Wenzl, H; Novacek, G.
[Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases].
Z Gastroenterol. 2018; 56(3):275-302
Doi: 10.1055/s-0044-100044
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hoegenauer Christoph
- Petritsch Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Anti-TNFα-antibodies have revolutionized the therapy of inflammatory bowel diseases and other immune-mediated inflammatory diseases. Due to the increasing application of these substances, the Working Group of Inflammatory Bowel Diseases of the Austrian Association of Gastroenterology and Hepatology intended to update their consensus report on the safe use of Infliximab (published in 2010) and to enlarge its scope to cover all anti-TNFα-antibodies. The present consensus report summarizes the current evidence on the safe use of anti-TNFα-antibodies and covers the following topics: general risk of infection, bacterial infections (i. e., Clostridium difficile, Tuberculosis, food hygiene), Pneumocystis jiroveci, viral infections (i. e., Hepatitis B, Hepatitis C, HIV, CMV, VZV), vaccination in general and recommendation for vaccines, gastrointestinal aspects (i. e., perianal fistula, abdominal fistula, intestinal strictures, stenosis and bowel obstruction), dermatologic aspects (skin malignancies, eczema-like drug-related skin eruption), infusion reactions and immunogenicity, demyelinating diseases, hepatotoxicity, haematotoxicity, congestive heart failure, risk and history of malignancies, and pregnancy and breast feeding. For practical reasons, the relevant aspects are summarized in a checklist which is divided into two parts: issues to be addressed before therapy and issues to be addressed during therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - therapeutic use
- Austria - administration & dosage
- Consensus - administration & dosage
- Female - administration & dosage
- Gastrointestinal Agents - therapeutic use
- Humans - administration & dosage
- Inflammatory Bowel Diseases - drug therapy, virology
- Infliximab - therapeutic use
- Pregnancy - administration & dosage
- Tumor Necrosis Factor-alpha - antagonists & inhibitors, immunology
- Find related publications in this database (Keywords)
- inflammatory bowel disease
- Infliximab
- Adalimumab
- Golimumab
- anti-TNF alpha
- infection
- safety
- malignancy
- vaccine
- pregnancy
- ulcerative colitis
- Crohn's disease